From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
June 24, 2020
Philadelphia, June 24, 2020 – IntegriChain, a leading data and managed services company helping Life Sciences manufacturers deliver access to innovative therapies that significantly improve patient lives, and the Chamber of Commerce for Greater Philadelphia’s regional CEO Council for Growth’s Cell & Gene Therapy and Connected Health Initiative, today announced a complimentary educational series for emerging cell and gene therapy companies. Focused on launch and commercial readiness, the three-part webinar series begins on Thursday, June 25. Programs continue on Thursday, July 16, and Thursday, August 20. Registration details are available here or by emailing info@ceocouncilforgrowth.com.
“Greater Philadelphia is the epicenter of explosive growth in cell and gene therapy, offering tremendous hope to patients battling very serious life-threatening conditions,” said Kevin Leininger, CEO of IntegriChain and member of the CEO Council for Growth. “Most of these companies are naturally focused on discovery and development. However, market access planning needs to be a key strategic effort to ensure patients can access these innovative therapies. That’s why more than 230 Life Sciences companies, including 15 cell and gene therapy companies, rely on us when they begin their launch planning. We are invested in the success of Greater Philadelphia’s cell and gene therapy industry and proud to partner with the CEO Council for Growth to share our expertise on therapy commercialization and access with these outstanding emerging companies.”
“On behalf of our Cell & Gene Therapy and Connected Health Initiative, we are pleased to partner with IntegriChain to present these important programs focused on one of the fastest growing subsectors of the life science and health care industry in our region – cell and gene therapy,” said Claire Marrazzo Greenwood, executive director, CEO Council for Growth. “Greater Philadelphia is recognized as a global hub of research, talent, capital, and companies in this industry. The complimentary educational series will contribute to the Initiative’s effort to develop critical infrastructure to ensure smooth transitions from concepts to products, and build a scalable ecosystem that supports growing and retaining companies, innovators, and expertise in the region.”
The three-part series for emerging cell and gene therapy companies features the following programs:
Launch Readiness for Cell & Gene Therapies in the Government & Commercial Channels: This webinar covers how cell and gene therapy companies can prepare for their government and commercial channels. The webinar will be held at 1:00 p.m. ET on Thursday, June 25, 2020.
Contracting Implications for Cell & Gene Therapies: This webinar examines the unique pricing and contracting strategies that can impact government program access of cell and gene therapies. The webinar will be held at 1:00 p.m. ET on Thursday, July 16, 2020.
Gross-to-Net Launch Readiness for Cell & Gene Therapies: This webinar focuses on mission-critical gross-to-net systems and forecasting activities for cell and gene therapy companies planning for commercial launch. The webinar will be held at 1:00 p.m. ET on August 20, 2020.
Greater Philadelphia is a leader in cell and gene therapy, from initial research launched more than two decades ago at the University to Pennsylvania, to emerging as one of the fastest-growing subsectors of the healthcare industry. Today, the science, research and development in cell and gene therapy that has originated from this region have resulted in six U.S. Food and Drug Administration (FDA) approvals, creating new pathways to cures for diseases, and improving and saving lives. As of 2019, the region is home to more than 30 cell and gene therapy companies. Collectively, these start-ups have raised more than $1 billion in invested capital, have created more than 3,000 jobs, and continue to bring capital, jobs and talent to the region.
The CEO Council for Growth, a council of the Chamber of Commerce for Greater Philadelphia, leads our region forward by envisioning a stronger, more competitive community, convening decision makers, taking action, and advocating for policies and practices that strengthen our regional economy. This team of more than 60 devoted business, higher education, and civic leaders reaches across our 11-county Greater Philadelphia community. They are engaged advocates who are committed to innovation in business, improving regional mobility, and fostering talent as key opportunities that define our competitive advantage and drive economic growth. For more information, visit https://www.ceocouncilforgrowth.com.
The Chamber, through its CEO Council for Growth, along with collaborating institutions, organizations and companies, has launched a multi-year initiative to leverage and promote Greater Philadelphia’s cell and gene therapy, gene editing, and connected health sectors. The objective of the initiative is to strengthen the region’s innovation economy through efforts including shared storytelling that builds awareness of the region’s assets, providing resources to start-up and scaling companies, assessing the talent needs of the sectors, and supporting the development of critical infrastructure for the sector’s growth. The initiative is supported by 11 partner companies, institutions and universities in the Greater Philadelphia region. Additional information is available at https://ceocouncilforgrowth.com/initiatives/cell-gene-therapy-and-connected-health/.
IntegriChain delivers Life Sciences’ only comprehensive data and business process platform for market access. More than 220 manufacturers rely on IntegriChain’s analytics, applications, managed services and expert advisors to power their market access operations and harness the value of their channel, patient and payer data. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Somerset, NJ, Raleigh, NC, and Pune, India. For more information, visit www.integrichain.com, or follow us on Twitter @IntegriChain and LinkedIn.
Contacts Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
